GlaxoSmithKline's consumer health business will be named Haleon following its planned spinoff and listing on the London Stock Exchange later this year, according to the drugmaker. The name of the ...

GSK plans to buy back £2 billion (S$3.4 billion) of shares as it raised its long-term growth outlook on optimism around its ...

(Reuters) - European shares were flat in early trade on Wednesday, as gains led by healthcare stocks following drugmaker Novo ...

Unrestricted access to all Essential and Insights content Access to the PRWeek Consultancy Tracker and the Top 150 Monthly Trading Tracker Hub In-depth reports including quarterly and annual ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.JzBkOQ-g.js ...

ICICI Direct recommended hold rating on GSK Consumer with a target price of ... of Boost and Horlicks will see lower volume growth in health food drinks and earnings growth over three years ...

We recently published a list of 12 Undervalued Defensive Stocks for 2025. In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against other undervalued defensive Stocks for ...

Harvey Jones isn't having much fun playing the GSK share price game. The FTSE 100 pharmaceutical stock must work hard to make ...

Jefferies analyst Peter Welford maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.50. The ...

Jan 7 (Reuters) - GSK (GSK.L), opens new tab and Pfizer's ... They had also flagged the risk of GBS. Sign up here. Healthcare & Pharmaceuticalscategory Trump order set to halt supply of HIV ...

J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.40.